Yahoo Finance

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...
mccormick.northwestern.edu

COMP_SCI 336: Design & Analysis of Algorithms

Algorithm design and analysis is fundamental to all areas of computer science and gives a rigorous framework for the study optimization. This course provides an introduction to algorithm design ...
EurekAlert!

Chip design with machine learning: a survey from algorithm perspective

This paper comprehensively surveys existing works of chip design with ML algorithms from an algorithm perspective. To accomplish this goal, the authors propose a novel and systematical taxonomy for ...
Nasdaq

Recursion Announces Collaboration With Roche, Genentech In Neuroscience And Oncology

(RTTNews) - Biotechnology company Recursion (RXRX) announced Tuesday a collaboration with Roche holding AG (ROG, RHHBY) and Genentech, a member of the Roche Group, to advance novel medicines to ...
The Globe and Mail

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first ...
Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...